STJ  St. Jude Medical Inc.

Exchange

NYSE

Sector

Health Care

Industry

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Market Cap.

18.673B

Vuru Grade

63.93/100

Current Price

$65.59
+0.72 (+1.11%)

Growth Price

$39.55
Overvalued by 39.70%

Stability Price

$20.48
Overvalued by 68.77%

Company Metrics

  • 20.9 P/E
  • 3.32 P/S
  • 4.64 P/B
  • 3.104 EPS
  • 13.07% Cash ROIC
  • 0.99 Cash Ratio
  • 1.04 / 1.6% Dividend
  • 1.53M Avg. Vol.
  • 284.69M Shares
  • 18.673B Market Cap.

Company Description

St. Jude Medical, Inc. develops, manufactures, and distributes cardiovascular and implantable neurostimulation medical devices worldwide. It operates in four segments: Cardiac Rhythm Management, Cardiovascular, Atrial Fibrillation, and Neuromodulation. The Cardiac Rhythm Management segment offers products for cardiac arrhythmias, or irregular heart beats. Its products include tachycardia implantab...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

St. Jude Medical Becomes Oversold
Forbes - Aug 7, 2014
In the case of St. Jude Medical, Inc., the RSI reading has hit 27.4 - by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 41.8.
St. Jude Medical Settles FDA Warnings Letter for Texas Plant
Zacks.com - Aug 27, 2014
St. Jude Medical Inc. (STJ - Analyst Report) revealed that U.S. Food and Drug Administration (FDA) notified that the company has addressed issues cited in the warning letter for its Plano facility in Texas.
St. Jude Medical Resolves FDA Warning Letter for Plano Facility - MarketWatch
St. Jude Medical Receives “Neutral” Rating from Zacks (STJ)
Ticker Report - 6 hours ago
Analysts at Sterne Agee initiated coverage on shares of St. Jude Medical in a research note on Tuesday, July 29th. They set a neutral rating and a $74.00 price target on the stock.
St. Jude Medical Completes Acquisition of NeuroTherm
Wall Street Journal - Aug 7, 2014
St. Jude Medical is the only medical device manufacturer with a chronic pain product portfolio that offers both radiofrequency ablation for spinal pain and spinal cord stimulation.
Large-scale Study Confirms Growing Body of Clinical Evidence for the St. Jude ...
MarketWatch - Aug 31, 2014
BARCELONA, Spain, Aug 31, 2014 (BUSINESS WIRE) -- St. Jude Medical, Inc. STJ, +1.11% a global medical device company, today announced results from a large-scale, clinical study concluding that the St. Jude Medical Quartet™ left-ventricular (LV) ...
ESC: Quadripolar Tops Bipolar in Cardiac Pacing - MedPage Today
St. Jude Medical to Present at the Morgan Stanley Global Healthcare Conference
MarketWatch - Aug 28, 2014
PAUL, Minn., Aug 28, 2014 (BUSINESS WIRE) -- St. Jude Medical, Inc. STJ, +1.11% will present at the Morgan Stanley Global Healthcare Conference on Tuesday, Sept.
St. Jude Medical Completes Acquiring Pain Solutions Maker
Yahoo News - Aug 13, 2014
St. Jude Medical Inc. (STJ) revealed that it has completed acquiring privately held chronic pain solutions maker NeuroTherm for cash payment of roughly $200 million.
New Clinical Trial Results Demonstrate Importance of St. Jude Medical ...
Stockhouse - 4 hours ago
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced a new multi-center clinical trial has found that using St. Jude Medical Fractional Flow Reserve (FFR) technology changed the course of treatment for more than one fifth ...
FAMOUS-NSTEMI: FFR Guidance Reduces Revascularization in NSTEMI - TCTMD
Fitch Affirms St. Jude Medical's at 'A'; Outlook Stable
MarketWatch - Aug 20, 2014
CHICAGO, Aug 20, 2014 (BUSINESS WIRE) -- Fitch Ratings has affirmed St. Jude Medical, Inc.'s (STJ) Issuer Default Rating (IDR) at 'A' with a Stable Rating Outlook.
St. Jude Medical (STJ) Shares Cross Below 200 DMA
NASDAQ - Aug 7, 2014
In trading on Thursday, shares of St. Jude Medical, Inc. (Symbol: STJ) crossed below their 200 day moving average of $63.72, changing hands as low as $63.34 per share.